Rodrigo A Bressan

List of Publications by Year
in descending order

32 papers	2,302 citations	331670 21 h-index	395702 33 g-index
33 all docs	33 docs citations	33 times ranked	3924 citing authors

#	Article	IF	Citations
1	Treatment-Resistant Schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) Working Group Consensus Guidelines on Diagnosis and Terminology. American Journal of Psychiatry, 2017, 174, 216-229.	7.2	685
2	Identifying Gene-Environment Interactions in Schizophrenia: Contemporary Challenges for Integrated, Large-scale Investigations. Schizophrenia Bulletin, 2014, 40, 729-736.	4.3	229
3	A general psychopathology factor (P factor) in children: Structural model analysis and external validation through familial risk and child global executive function.. Journal of Abnormal Psychology, 2017, 126, 137-148.	1.9	189
4	Ventral Striatum Functional Connectivity as a Predictor of Adolescent Depressive Disorder in a Longitudinal Community-Based Sample. American Journal of Psychiatry, 2017, 174, 1112-1119.	7.2	130
5	Is Regionally Selective D2/D3Dopamine Occupancy Sufficient for Atypical Antipsychotic Effect? An In Vivo Quantitative [123I]Epidepride SPET Study of Amisulpride-Treated Patients. American Journal of Psychiatry, 2003, 160, 1413-1420.	7.2	112
6	Relationship between ketamine-induced psychotic symptoms and NMDA receptor occupancyâ€"a [123I]CNS-1261 SPET study. Psychopharmacology, 2008, 197, 401-408.	3.1	89
7	Impact of peripheral levels of chemokines, BDNF and oxidative markers on cognition in individuals with schizophrenia. Journal of Psychiatric Research, 2013, 47, 1376-1382.	3.1	84
8	Polygenic Risk Score for Alzheimerâ€™s Disease: Implications for Memory Performance and Hippocampal Volumes in Early Life. American Journal of Psychiatry, 2018, 175, 555-563.	7.2	75
9	Typical antipsychotic drugs â€" D2 receptor occupancy and depressive symptoms in schizophrenia. Schizophrenia Research, 2002, 56, 31-36.	2.0	71
10	Structural validity and reliability of the Positive and Negative Affect Schedule (PANAS): Evidence from a large Brazilian community sample. Revista Brasileira De Psiquiatria, 2013, 35, 169-172.	1.7	69
11	Development of Proteomic Prediction Models for Transition to Psychotic Disorder in the Clinical High-Risk State and Psychotic Experiences in Adolescence. JAMA Psychiatry, 2021, 78, 77.	11.0	57
12	Depressive episodes in stable schizophrenia: critical evaluation of the DSM-IV and ICD-10 diagnostic criteria. Psychiatry Research, 2003, 117, 47-56.	3.3	56
13	Peripheral interleukin-2 level is associated with negative symptoms and cognitive performance in schizophrenia. Physiology and Behavior, 2014, 129, 194-198.	2.1	49
14	Kinetic modelling of [123I]CNS 1261â€"a potential SPET tracer for the NMDA receptor. Nuclear Medicine and Biology, 2003, 30, 441-454.	0.6	46
15	Prolactinemia is uncoupled from central D2/D3 dopamine receptor occupancy in amisulpride treated patients. Psychopharmacology, 2004, 175, 367-373.	3.1	38
16	Violence and post-traumatic stress disorder in Sao Paulo and Rio de Janeiro, Brazil: the protocol for an epidemiological and genetic survey. BMC Psychiatry, 2009, 9, 34.	2.6	38
17	Can neuroimaging be used to predict the onset of psychosis?. Lancet Psychiatry,the, 2015, 2, 1117-1122.	7.4	36
18	Ketamine displaces the novel NMDA receptor SPET probe [123I]CNS-1261 in humans in vivo. Nuclear Medicine and Biology, 2006, 33, 239-243.	0.6	34

#	Article	IF	Citations
19	A bolus/infusion paradigm for the novel NMDA receptor SPET tracer [123i]CNS 1261. Nuclear Medicine and Biology, 2004, 31, 155-164.	0.6	30
20	Is semantic verbal fluency impairment explained by executive function deficits in schizophrenia?. Revista Brasileira De Psiquiatria, 2016, 38, 121-126.	1.7	27
21	Cognitive functioning throughout adulthood and illness stages in individuals with psychotic disorders and their unaffected siblings. Molecular Psychiatry, 2021, 26, 4529-4543.	7.9	23
22	Non-uniform blockade of intrastriatal D2/D3 receptors by risperidone and amisulpride. Psychopharmacology, 2005, 180, 664-669.	3.1	21
23	Serum brain-derived neurotrophic factor and cortical thickness are differently related in patients with schizophrenia and controls. Psychiatry Research - Neuroimaging, 2015, 234, 84-89.	1.8	16
24	A symptom combination predicting treatment-resistant schizophrenia â€" A strategy for real-world clinical practice. Schizophrenia Research, 2020, 218, 195-200.	2.0	16
25	Evaluation of NMDA Receptorsin Vivoin Schizophrenic Patients with [123I]CNS 1261 and SPET. Annals of the New York Academy of Sciences, 2003, 1003, 364-367.	3.8	13
26	The joint structure of major depression, anxiety disorders, and trait negative affect. Revista Brasileira De Psiquiatria, 2014, 36, 285-292.	1.7	13
27	Component mechanisms of executive function in schizophrenia and their contribution to functional outcomes. Revista Brasileira De Psiquiatria, 2019, 41, 22-30.	1.7	12
28	Childhood trauma and adolescent psychotic experiences in a community-based cohort: The potential role of positive attributes as a protective factor. Schizophrenia Research, 2019, 205, 23-29.	2.0	11
29	Management of schizophrenia: clinical experience with asenapine. Journal of Psychopharmacology, 2013, 27, 14-22.	4.0	10
30	Psychotic-like Experiences and Common Mental Disorders in Childhood and Adolescence: Bidirectional and Transdiagnostic Associations in a Longitudinal Community-based Study. Schizophrenia Bulletin Open, 2021, 2, .	1.7	10
31	Testing Measurement Invariance across Groups of Children with and without Attention-Deficit/Hyperactivity Disorder: Applications for Word Recognition and Spelling Tasks. Frontiers in Psychology, 2017, 8, 1891.	2.1	6
32	Population neuroscience: challenges and opportunities for psychiatric research in low- and middle-income countries. Revista Brasileira De Psiquiatria, 2020, 42, 442-448.	1.7	5